



AUG 08 2007

PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB No. 1115-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCEIPB
1646

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	SB/08 Form 82 U.S. Patent Documents 75 Foreign Patent Documents 84 Non-Patent Documents
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature			
Printed name	Emily R. Whelan		
Date	August 6, 2007	Reg. No.	50,391

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 6, 2007

Signature: (Kristen Mousallin)

6311897
USPTO/DOCS 6311897.v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/

O I P E
AUG 08 2007
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: August 6, 2007

Signature: 
(Kristen Mousallie)

Docket No.: 2200437.00120US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregor CEVC

Confirmation No.: TBD

Application No.: 09/890,371

Art Unit: 1646

Filed: April 8, 2002

Examiner: B. D. Hissong

Title: TRANSNASAL TRANSPORT/IMMUNISATION WITH HIGHLY ADAPTABLE CARRIERS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT (IDS)

Dear Sir:


This Information Disclosure Statement is being filed prior to the mailing date of a first Office Action on the merits after a Request for Continued Examination. No fee is required.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 08-0219, under Order No. 2200437.00120US1 from which the undersigned is authorized to draw.

Respectfully submitted,

Dated: August 6, 2007


Emily R. Whelan
Registration No.: 50,391
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000 (telephone)
(617) 526-5000 (facsimile)

6311896
US1DOCS 6311896v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

10

Complete If Known

Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-20010012849-A1	08-09-2001	Wechter		
AB*	US-20020003179-A1	01-10-2002	Verhoff et al.		
AC*	US-20020012680-A1	01-31-2002	Patel et al.		
AD*	US-20020037877-A1	03-28-2002	Singh		
AE*	US-20020048596-A1	04-25-2002	CEVC		
AF*	US-20020106345-A1	08-08-2002	Uhrich et al.		
AG*	US-20020191988-A1	08-29-2002	Niemiec et al.		
AH*	US-20020147238-A1	10-10-2002	Jerussi et al.		
AI*	US-20030099694-A1	05-29-2003	Cevc et al.		
AJ*	US-20040071767-A1	04-15-2004	Cevc et al.		
AK*	US-20040105881-A1	06-03-2004	Cevc et al.		
AL*	US-20050123897-A1	06-09-2005	Cevc et al.		
AM*	US-20070031483	02-08-2007	Cevc		
AN*	US-4,369,182	01-18-1983	Ghyczy et al.		
AO*	US-4,619,794	10-28-1986	Hauser et al.		
AP*	US-4,666,747	05-19-1987	Quinn et al.		
AO*	US-4,731,210	03-15-1988	Weder et al.		
AR*	US-4,746,509	05-24-1988	Haggagie et al.		
AS*	US-4,783,450	11-08-1988	Fawzi et al.		
AT*	US-4,849,224	07-18-1989	Chang et al.		
AU*	US-4,911,928	03-27-1990	Wallach		
AV*	US-4,921,706	05-01-1990	Roberts et al.		
AW*	US-4,937,078	06-26-1990	Mezel et al.		
AX*	US-4,937,254	06-26-1990	Sheffield et al.		
AY*	US-4,944,948	07-31-1990	Uster et al.		
AZ*	US-4,954,345	09-04-1990	Muller et al.		
AA1*	US-4,983,395	01-08-1991	Chang et al.		
AB1*	US-5,104,661	04-14-1992	Lau		
AC1*	US-5,145,684	09-08-1992	Liversidge et al.		
AD1*	US-5,154,930	10-13-1992	Popescu et al.		
AE1*	US-5,202,125	04-13-1993	Ebert et al.		
AF1*	US-5,209,720	05-11-1993	Unger		
AG1*	US-5,238,613	08-24-1993	Anderson		
AH1*	US-5,244,678	09-14-1993	Legros et al.		
AI1*	US-5,322,685	06-21-1994	Nakagawa et al.		
AJ1*	US-5,460,820	10-24-1995	Ebert et al.		
AK1*	US-5,498,418	03-12-1996	Beutner et al.		
AL1*	US-5,510,118	04-23-1996	Bosch et al.		
AM1*	US-5,552,160	09-03-1996	Liversidge et al.		
AN1*	US-5,585,109	12-17-1996	Hayward et al.		
AO1*	US-5,607,692	04-04-1997	Ribier et al.		
AP1*	US-5,614,178	03-25-1997	Bloom et al.		
AQ1*	US-5,648,095	07-15-1997	Illum et al.		
AR1*	US-5,654,337	08-05-1997	Roentsch et al.		
AS1*	US-5,681,849	10-08-1997	Richter et al.		

Examiner Signature	/Bruce Hissong/	Date Considered	12/10/2010
--------------------	-----------------	-----------------	------------

6311914v4

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/

US100CS 6311914v4



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

10

Complete if Known

Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

AT1*	US-5,716,638	02-10-1998	Touitou et al.
AU1*	US-5,741,515	04-21-1998	Ciceri et al.
AV1*	US-5,763,422	06-09-1998	Lichtenberger et al.
AW1*	US-5,783,208	07-21-1998	Venkateshwaran et al.
AX1*	US-5,837,289	11-17-1998	Grasela et al.
AY1*	US-5,858,330	01-12-1999	Boltri et al.
AZ1*	US-5,874,095	02-23-1999	Deckner et al.
AA2*	US-5,874,422	02-23-1999	Krause et al.
AB2*	US-5,891,472	04-06-1999	Russell
AC2*	US-5,958,379	09-28-1999	Regenold et al.
AD2*	US-5,985,860	11-16-1999	Toppi
AE2*	US-6,028,066	02-22-2000	Unger
AF2*	US-6,045,827	04-04-2000	Russell
AG2*	US-6,069,172	05-30-2000	Bertini et al.
AH2*	US-6,083,996	07-04-2000	Buyuktimkin et al.
AI2*	US-6,193,996	02-27-2001	Effing et al.
AJ2*	US-6,200,598	03-13-2001	Needham
AK2*	US-6,214,386	04-10-2001	Santur et al.
AL2*	US-6,248,353	06-19-2001	Singh
AM2*	US-6,276,598	08-21-2001	Chi Cheng
AN2*	US-6,277,892	08-21-2001	Deckner et al.
AO2*	US-6,294,192	09-25-2001	Patel et al.
AP2*	US-6,303,141	10-16-2001	Fischer et al.
AQ2*	US-6,387,383	05-14-2002	Dow et al.
AR2*	US-6,448,296-A1	09-10-2002	Yasueda et al.
AS2*	US-6,451,339-A1	09-17-2002	Patel et al.
AT2*	US-6,562,370-A1	05-13-2003	Luo et al.
AU2*	US-6,577,880	06-10-2003	Ishida et al.
AV2*	US-6,582,724-A1	06-24-2003	Hsu et al.
AW2*	US-6,586,000-A1	07-01-2003	Luo et al.
AX2*	US-6,645,520-A1	11-11-2003	Hsu et al.
AY2*	US-6,645,529-A1	11-11-2003	Gergely et al.
AZ2*	US-6,726,598	04-27-2004	Jarvis et al.
AA3*	US-6,797,276	09-28-2004	Glenn et al.
AB3*	US-6,835,392-A1	12-28-2004	Hsu et al.
AC3*	US-6,868,686-A1	03-22-2005	Ueda et al.
AD3*	US-RE33,273	07-24-1990	Speaker

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cits No.	Foreign Patent Document Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	# ⁶
BA	AU-724218		09-14-2000	IDEA		
BB	AU-1740283		07-28-1983	Ciba Geigy AG		
BC	CA-1143656		03-29-1983	Kureha Kagaku Kogyo Kabushiki Kaisha		
BD	CA-2052164		09-26-1992	HARA, TOSHI FUMI		
BE	CA-2067754		02-25-1992	IDEA AG		
BF	CA-2160775		11-24-1994	Merck Patent GMBH, et al.		

Examiner Signature /Bruce Hissong/

Date Considered

12/10/2010

6311914

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/

US100GS 6311914v1



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

10

Complete If Known

Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

BG	CA-1289420	09-24-1991	Micro-Pak Inc.	
BH	DE-3,713,494	10-29-1987	L'Oreal	
BI	DE-3016976	11-13-1980	Kureha Kagaku Kogyo	
BJ	EP-0475160	03-18-1992	Ceva	
BK	EP-0152379	08-21-1985	Ciba Geigy AG	
BL	EP-0382716	01-28-1998	WARNER-LAMBERT CO.	
BM	EP-1031347	04-17-2002	IDEA AG	
BN	EP-0707847	04-24-1996	Bayer AG	
BO	EP-0088046	09-07-1983	Ciba Geigy Ag	✓
BP	EP-0995435	04-26-2000	SENJU PHARMACEUTICAL CO., LTD.	
BQ	EP-0220797	05-06-1987	Nikko Chemicals Co. Ltd.	
BR	EP-0280492	08-31-1988	Takeda Chemical Industries, Ltd.	
BS	EP-0704206	04-03-1996	Regenold, Jurgen	
BT	EP-0298280	06-14-1988	Happgood, CV	
BU	EP-0355095	08-04-1993	THE LIPOSOME COMPANY, INC.	
BV	EP-1031346	05-02-2002	IDEA AG	
BW	EP-0211647	02-25-1987	Allergan Pharmaceuticals, Inc.	
BX	EP-0224837	11-24-1986	Rohm Pharma GmbH	
BY	EP-0674913	04-10-1995	LecTec Corporation	
BZ	EP-0102324	03-07-1984	Ciba-Geigy AG	
BA1	EP-0582239	02-09-1994	RHONE-POULENC RORER GMBH	
BB1	EP-0393707	10-24-1990	Otsuka Pharmaceutical Co.	
BC1	JP-07-324029	12-12-1995	L'Oreal SA	
BD1	JP-61-271204	12-01-1986	Shiseido Co Ltd.	
BE1	WO-91/04013	04-04-1991	MICRO VESICULAR SYSTEMS, INC.	
BF1	WO-88/07362	10-06-1988	LIPOSOME TECHNOLOGY, INC.	
BG1	WO-90/09782	09-07-1990	LIPOSOME TECHNOLOGY, INC.	
BH1	WO-01/01963	01-11-2001	IDEA AG	✓
BI1	WO-98/07414	02-26-1998	RESEARCH TRIANGLE PHARMACEUTICALS LTD.	✓
BJ1	WO-96/04526	02-15-1996	SIEMENS AUTOMOTIVE CORPORATION	
BK1	WO-02/07767	01-31-2002	LIPOCINE, INC.	✓
BL1	WO-02/11683	02-14-2002	DOW PHARMACEUTICAL SCIENCES	✓
BM1	WO-00/00597	01-06-2000	The University of Manitoba	
BN1	WO-96/19205	06-27-1996	Theratech, Inc.	✓
BO1	WO-01/12155	02-22-2001	LIPOCINE, INC.	✓

Examiner Signature	/Bruce Hissong/	Date Considered	12/10/2010
--------------------	-----------------	-----------------	------------

6311914

US100CS 6311934v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

4

of

10

Complete if Known	
Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

BP1	WO-04/032900	04-22-2004	IDEA AG	
BQ1	WO-98/17255	04-30-1998	Cevc Gregor	✓
BR1	WO-96/29999	10-03-1996	HEXAL AG	✓
BS1	WO-01/00247	01-04-2001	The Liposome Company, Inc	
BT1	WO-00/25822	05-11-2000	John C. Grasela, et al.	✓
BU1	WO-00/44349	08-03-2000	IDEA AG	
BV1	WO-98/05539	02-12-1998	TOYOTA JIDOSHA KABUSHIKI KAISHA	
BW1	WO-00/44350	08-03-2000	IDEA AG	
BX1	WO-00/50007	08-31-2000	LIPOCINE, INC.	✓
BY1	WO-98/24407	06-11-1998	L'Oreal	
BZ1	WO-98/06750	02-19-1998	KEYGENE N.V.	
BA2	WO-87/01938	04-09-1987	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	
BB2	WO-95/35095	12-28-1995	YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM	
BC2	WO-02/058670	08-01-2002	Eurocelltique S.A.	
BD2	WO-91/01596	02-07-1991	SHAH, Reza H.	
BE2	WO-00/24377	05-04-2000	Idea Innovat Dermale Appl GmbH et al.	✓
BF2	WO-92/03122	03-05-1992	Cevc	
BG2	WO-98/30215	07-16-1998	Cilag AG	
BH2	WO-92/22292	12-23-1992	SCHWARZ PHARMA AG	✓
BI2	WO-00/38653	07-06-2000	Cevc	
BJ2	WO-93/19737	10-14-1993	KABI PHARMACIA AB	
BK2	WO-05/063213	07-14-2005	Biodelivery Sciences International, Inc	
BL2	WO-95/09831	04-13-1995	Nicox Ltd et al.	
BM2	WO-06/050926	05-18-2006	IDEA AG	
BN2	WO-02/32398	04-25-2002	Massachusetts Institute of Technology	
BO2	WO-98/33483	08-06-1998	DEPOTECH CORPORATION	
BP2	WO-93/19736	10-14-1993	KABI PHARMACIA AB	
BQ2	WO-01/01962	01-11-2001	IDEA Innovative GmbH	✓
BR2	WO-90/11065	10-04-1990	Theratech, Inc.	✓
BS2	WO-00/13684	03-16-2000	LOMA LINDA UNIVERSITY MEDICAL CENTER	✓
BT2	WO-94/26257	11-24-1994	LTS LOHMANN THERAPIE-SYSTEME GMBH & CO.	✓
BU2	WO-00/12060	03-09-2000	Cevc	
BV2	WO-92/05771	04-16-1992	KABI PHARMACIA	
BW2	WO-99/22703	05-14-1999	LURIDENT LTD.	✓

Examiner Signature	12/10/2010	Date Considered	12/10/2010
--------------------	------------	-----------------	------------

6311914

USPTO/DOCS 6311914.dwt

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

				Complete if Known
Application Number				09/890,371
Filing Date				April 8, 2002
First Named Inventor				Gregor CEVC
Art Unit				1646
Examiner Name				B. D. Hissong
Sheet	5	of	10	Attorney Docket Number 2200437.00120US1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are available with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. * Applicant's unique citation designation number (optional). * See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ² Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁴ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
GA	Abstract searched from Derwent World Patents Index Latest, for EP 0102 324.		
CB	Almeida et al., "Nasal delivery of vaccines," Journal of Drug Targeting, Vol 3, No 6, pp. 455-67 (1996)		
CC	Aungst et al., "Enhancement of Naloxone Penetration Through Human Skin In Vitro Using Fatty Acids, Fatty Alcohols, Surfactants, Sulfoxides and Amides," on International Journal of Pharmaceutics, 33 (1986) pp. 225-234.		
CD	Benner, "The Human Body. The Wonderwork of the Human Body, Structure, Functions, Interactions, Processes and Mechanisms," Weltbild GmbH Augsburg (1995)		
CE	Berger, M. Oral insulin 1922-1992: The History of Continuous Ambition and Failure" Heinrich-Heine-Universität, Düsseldorf, Germany		
CF	Beyer, C. et al., "Micro Emulsions" Pharmazie in unserer Zeit, No. 2 (1983).		
CG	Blume, et al., "Drug-Carrier and Stability Properties of the Long-Lived Lipid Vesicles, Cryptosomes, In Vitro and In Vivo," Journal of Liposome Research, 2(3), 355-368 (1992).		
CH	Brendzel, A. et al., "Effects of Lipid-Soluble Substances on the Thermotropic Properties of Liposome Filtration," Biochimica et Biophysica Acta, 601 (1980) 260-270.		
CI	Burnette, R. et al., "Characterization of the Permeselective Properties of Excised Human Skin During Lymphophoresis," Journal of Pharmaceutical Sciences / Vol. 76, No. 10, October 1987 pgs. 765-773.		
CJ	Byas-Smith et al., "Transdermal clonidine compared to placebo in painful diabetic neuropathy using two stage 'enriched enrollment' design," Pain, Vol 60, pp. 267-274 (1995)		
CK	Calpena, et al., "Influence of the Formulation on the In Vitro Transdermal Penetration of Sodium Diclofenac," Arzneim.-Forsch./Drug Res., 49(II), 1012-1017 (1999).		
CL	Carafa, M. et al."Diclofenac-loaded Non-ionic Surfactant Vesicles: Characterization and In Vitro Permeation Studies," International Journal of Pharmaceutics 231 (2002) 21-32.		
CM	Castille et al., "Glucocorticoids Prolong Rat Sciatic Nerve Blockade In Vivo from Bupivacaine Microspheres," Anesthesia, Vol 85, No 5, pp. 1157-66 (1996)		
CN	Cevc et al., "Phospholipids handbook", Marcel Dekker, Inc., New York, Basel, Hong Kong, pp. 375-376 and 404 (1993)		
CO	Cevc et al.: "Transdermal drug carriers: basic properties, optimization and transfer efficiency in the case of epicutaneously applied peptides," J. Contr. Rel., 36, pp. 3-16, 1995.		
CP	Cevc, "Transfomers, Liposomes, and Other Lipid Suspensions on the Skin: Permeation Enhancement, Vesicle Penetration, and Transdermal Drug Delivery," Crit. Rev. Ther. Drug Carrier Syst., 13 (3&4), pp. 257-388, 1996.		
CQ	Cevc, G. et al."New, Highly Efficient Formulation of Diclofenac for the Topical, Transdermal Administration in Ultradeformable Drug Carriers, Transfersomes," Biochimica et Biophysica Acta 1514 (2001) 191-205.		
CR	Cevc, G. et al., "The skin: a pathway for systemic treatment with patches and lipid-based		

Examiner Signature	/Bruce Hissong/	Date Considered	12/10/2010
--------------------	-----------------	-----------------	------------

6311914v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

6

of

10

Complete if Known

Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

	agent carriers" Advanced Drug Delivery Reviews 18 pp. 349-378 (1996).	
CS	Cevc, G. et al., "Transfomes-mediated transepidermal delivery improves the regio-specificity and biological activity of corticosteroids in vivo," JOURNAL OF CONTROLLED RELEASE, vol. 45, no. 3, 1997, pages 211-226.	
CT	Cevc, G., "Material Transport Across Permeability Barriers by Means of Lipid Vesicles", Handbook of Biological Physics, Vol. 1, pp. 465-490 (1995).	
CU	Claims (pending) filed February 9, 2007, in connection with U.S. Patent Application No. 09/555,986, under examination by Examiner Kishore of the USPTO.	
CV	Claims (pending) filed May 8, 2007, in connection with U.S. Patent Application No. 11/667,325	
CW	Claims filed February 26, 2007, in connection with U.S. Patent Application No. 10/984,450 (U.S. Patent Publication No. US 2005/0123897 A1), under examination by Examiner Fortuna of the USPTO.	
CX	Claims filed January 22, 2007, in connection with U.S. Patent Application No. 10/037,480 (U.S. Patent Publication No. US 2003/0099694 A1), under examination by Examiner Fortuna of the USPTO.	
CY	Claims filed July 12, 2007, in connection with U.S. Patent Application No. 09/284,683 (U.S. Patent Publication No. US 2002/0048596 A1), under examination by Examiner Kishore of the USPTO.	
CZ	Claims filed June 20, 2007, in connection with U.S. Patent Application No. 10/357,618 (U.S. Patent Publication No. US 2005/0105881 A1), under examination by Examiner Ghali of the USPTO.	
CA1	Claims filed October 11, 2006, in connection with U.S. Patent Application No. 11/545,904 (U.S. Patent Publication No. US 2007/0031483 A1), under examination by Examiner Ghali of the USPTO.	
CB1	Claims filed October 20, 2006, in connection with U.S. Patent Application No. 10/357,617 (U.S. Patent Publication No. US 2004/0071767 A1), under examination by Examiner Kishore of the USPTO.	
CC1	Clark, J.M., Jr. "Experimental Biochemistry." Biochemistry Division, Department of Chemistry, University of Illinois, pp. 47-48.	
CD1	Copy of International Search Report for International Patent Application No. PCT/EP2005/011986. (July 4, 2006).	
CE1	Definition of Micropicide, Wikipedia, The Free Online encyclopedia (2007)	
CF1	Edwards, et al., Effects of Triton X-100 on Saponated Lecithin Vesicles, Langmuir, Vol. 5, pages 472-475 (1989).	
CG1	Fieser, L. F. et al. "Organische Chemie," Hans Ruprecht Hensel, 2nd revised edition, Verlag Chemie GmbH, Weinheim/Bergstr. page 1250 (1968).	
CH1	FLUKA Chemica-BioChemica, Katalog 16, pages 204, 830 (1988/1989)	
CI1	Foldvari, "Effect of Vehicle on Topical Liposomal Drug Delivery: Petrolatum Bases," J. Microencapsulation, 1996, Vol. 13, No. 5, 589-600.	
CJ1	Foldvari, "In Vitro cutaneous and Percutaneous Delivery and in Vivo Efficacy of Tetracaine from Liposomal and Conventional Vehicles," Pharmaceutical Research, Vol. 11, No. 11, 1994.	
CK1	Foldvari, et al., "Dermal Drug Delivery by Liposome Encapsulation: Clinical and Electron Microscopic Studies," J. Microencapsulation, 1990, Vol. 7, No. 4, 479-489.	
CL1	Frantzen et al., "Assessing the accuracy of routine Photon Correlation Spectroscopy Analysis of Heterogeneous Size Distributions," AAPS PharmSciTech, Vol 4, No 3, Article 36, pp.1-9 (2003)	
CM1	Friedrich, I. et al., "Physicochemical Characterization of a Reverse Micellar Solution after Loading with Different Drugs," Pharmazie 55 (2000) 10, 755-758.	

Examiner Signature 6311914	/Bruce Hissong/	Date Considered	12/10/2010
-------------------------------	-----------------	-----------------	------------

USIDOC5 6311914v1
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

7

of

10

		Complete if Known	
Application Number	09/890,371		
Filing Date	April 8, 2002		
First Named Inventor	Gregor CEVC		
Art Unit	1646		
Examiner Name	B. D. Hissong		
Attorney Docket Number	2200437.00120US1		

CN1	Gesztes, A. et al., "Topical Anesthesia of the Skin by Liposome-Encapsulated Tetracaine, Anesth Analg 1988 67 1079-1081.	
CO1	Golden et al., "Role of Stratum Corneum Lipid Fluidity Transdermal Drug Flux," on Journal of Pharmaceutical Sciences Vol. 76, No. 1, January 1987, American Pharmaceuticals Association, pp. 25-28.	
CP1	Grahame R, "Transdermal non-steroidal anti-inflammatory agents," BJCP, Vol 49, No1, pp. 33-35 (Jan/Feb 1995)	
CQ1	Green et al., "In Vitro and In Vivo Enhancement of Skin Permeation with Oleic and Lauric Acids," on International Journal of Pharmaceutics, 48 (1988), pp. 103-111.	
CR1	Helenius, et al., "Solubilization of Membranes by Detergents," Biochimica et Biophysica Acta, 415 (1975) 29-79.	
CS1	Henni, T. et al., "Application of an Oily Gel Formed by Hydrogenated Soybean Phospholipids as a Percutaneous Absorption-Type Ointment Base," Chem. Pharm. Bull. 42(3) 651-655 (1994).	
CT1	Holzbach RT, "Detection of Vesicles in native and model Biles by Morphological and other structural Techniques: applications and limitations," Hepatology, Sep12 (3 Pt 2), pp. 106S-112S (1990)	
CU1	Ito, Yoshimasa et al. "Percutaneous Absorption of Acemetacin from a Membrane Controlled Transdermal System and Prediction of the Disposition of the Drug in Rats." Biol. Pharm. Bull., 16(6):583-588. (1993).	
CV1	Jackson, M. L. et al. "Solubilization of Phosphatidylcholine Bilayers by Octyl Glucoside" Biochemistry, Vol. 21, pages 4576-4582 (1982)	
GW1	Koren and R.K. Liedtke, "Mechanism Transcutaneous Resorption," on Grundlagen/Basics, pp. 1487-1491.	
CX1	Katoulis et al., "Efficacy of a New Needleless Insulin Delivery System Monitoring of Blood Glucose Fluctuations and Free Insulin Levels," on International Journal of Artificial Organs Vol. 12, No. 5, 1989, pp. 333-338.	
CY1	Kilbanov, et al., "Activity of amphiphatic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target, BBA, 1062, pp. 141-148, 1991.	
CZ1	Knepf et al., "CONTROLLED DRUG RELEASE FROM A NOVEL LIPOSOMAL DELIVERY SYSTEM II. TRANSDERMAL DELIVERY CHARACTERISTICS," Journal of Controlled Release 12 (1990) March, No. 1, Amsterdam, NL, pp. 25-30.	
CA2	Lasch, J. et al., "Interactions of external lipids (lipids vesicles) with the skin" Journal of Liposome Research 5(3) pp. 543-569 (1995).	
CB2	Lehmann, J. et al., "Analgesic and anti-inflammatory efficacy of IDEA-070 in UVB-induced sunburn," Journal of the European Academy of Dermatology and Venereology, 18(S2):167-168. (October 2004).	
CC2	Lichtenberg, D. et al., "Solubilization of Phospholipids by Detergents Structural and Kinetic Aspects" Biochimica et Biophysica Acta, 737 pp. 285-304 (1983).	
CD2	Lobbecke, et al., "Effects of Short-Chain Alcohols on the Phase Behavior and Interdigitation of Phosphatidylcholine Bilayer Membranes," Biochimica et Biophysica Acta 1237 (1995) 59-69.	
CE2	Mayer, L.D. et al., "Vesicles of variable sizes produced by a rapid extrusion procedure," Biochimica et Biophysica Acta, 858 pp. 161-165 (1986).	
CF2	Merck Index: 10th Edition. 1983, pages 779-780.	
CG2	Mezei, "Liposomes as a Skin Drug Delivery System," 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp. 345-358.	
CH2	Ogiso, Taro et al. "Membrane-Controlled Transdermal Therapeutic System Containing Clonazepam and Anticonvulsant Activity after its Application." Chem. Pharm. Bull., 37(2):446-	

Examiner Signature
6311914

/Bruce Hissong/

Date Considered

12/10/2010



Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

8

of

10

Complete If Known

Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

	449. (1989).	
CI2	Patel, H.M. et al., "Oral Administration of Insulin By Encapsulation Within Liposomes," Febs Letters, 62(1):60-63 (February 1976).	
CS2	Patel, H.M., "Liposomes as a Controlled-release System," Biomedical Society Transactions 609th Meeting, Lees, pp. 513-516.	
CK2	Paul et al., "Transdermal immunisation with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes," Vaccine, Vol 16, No 2-3, pp. 188-195 (Jan 1998).	
CL2	Peters, et al., "Pharmacodynamics of a Liposomal Preparation for Local Anaesthesia," Arzneim.-Forsch./Dru Res. 45(II), Nr 12 (1995).	
CM2	Planas, et al., "Noninvasive Percutaneous Induction of Topical Analgesia by a New Type of Drug Carrier, and Prolongation of Local Pain Insensitivity by Anesthetic Liposomes," Anesth Analg, 1992, 75 615-621.	
CN2	Price, C. E. "A Review of the Factors Influencing the Penetration of Pesticides Through Plant Leaves," on I.C.I. Ltd., Plant Protection Division, Jealott's Hill Research Station, Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252.	
CO2	Product Information, "Polysorbate 80 VG" (2004)	
CP2	Product Information, "Tween 80 Pure" (2004)	
CO2	Prof. Dr. K-U Benner, <i>Der Körper des Menschen</i> , Chapter 4, page 49 (1995).	
CR2	Ranade V., "Drug Delivery Systems 6. Transdermal Drug Delivery," J. Clin Pharmacol, Vol 31, pp. 401-418 (1991)	
CS2	Roeding, J. "Liposomes and Niosomes in Pharmacy and Cosmetics State of Art Prospects, Techniques of Visualizing Vesicular Systems, Interaction of Liposomes with the Skin" Training Course No. 105 from May 14-16, 1990. Maritim Hotel Nurnberg, Frauentorgraben 11, 8500 Nurnberg.	
CT2	Schramlová, J. et al., "The Effect of an Antiphlogistic Incorporated in Liposomes on Experimentally Induced Inflammation," Folia Biologica (Praha) 43, 195-199 (1997).	
CU2	Schreier, H. "Liposomes - A Novel Drug Carrier. I. Phospholipids; Production and Characterization of Liposomes; II. Destiny of liposomes in vivo: use in therapy," Pharmazie in unserer Zeit, No. 4 (1982).	
CV2	SERVA Feinbiochemica, Katalog, pages 201-202 (1986/1987).	
CW2	Siddiqui, O. et al., "Nonparenteral Administration of Peptide and Protein Drugs," CRC Critical Reviews in Therapeutic Drug Carrier Systems, Volume 3, Issue 3 pg. 195-208.	
CX2	Stoye, I. et al., "Transformation of a Liposomal Dispersion Containing Ibuprofen Lysinate and Phospholipids into Mixed Micelles - Physico-chemical Characterization and Influence on Drug Permeation through Excised Human Stratum Corneum," European Journal of Pharmaceuticals and Biopharmaceuticals 46 (1998) 191-200.	
CY2	Swenson, E. Scott and William J. Curatolo, "Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity," Advanced Drug Delivery Reviews, 8:39-92, (1992).	
CZ2	Trotta, M. et al., "Deformable liposomes for dermal administration of methotrexate," INTERNATIONAL JOURNAL OF PHARMACEUTICALS (KIDLINGTON), vol. 270, no. 1-2, 11 February 2004, pages 119-125.	
CA3	Trotta, M. et al., "Elastic liposomes for skin delivery of dipotassium glycyrrhizinate," INTERNATIONAL JOURNAL OF PHARMACEUTICALS (KIDLINGTON), vol. 241, no. 2, 25 July 2002, pages 319-327.	
CB3	Valenta, C. et al., "Evaluation of Novel Soya-lecithin Formulations for Dermal use containing Ketoprofen as a Model Drug," Journal of Controlled Release 63 (2000) 165-173.	

Examiner Signature 6311914	/Bruce Hissong/	Date Considered	12/10/2010
-------------------------------	-----------------	-----------------	------------



Used in Lieu of PTO/SB/08/A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

9

of

10

Complete if Known

Application Number	09/890,371
Filing Date	April 8, 2002
First Named Inventor	Gregor CEVC
Art Unit	1646
Examiner Name	B. D. Hissong
Attorney Docket Number	2200437.00120US1

CC3	Vinson, P. et al., "Vesicle-Micelle Transition of Phosphatidylcholine Bilayers by Octyl Glucoside Elucidated by Cryo-Transmission Electron Microscopy," Biophys. J., Biophysical Society Volume 56, October 1989 669-681.	
CD3	Vyas et al., "Liposomally Encapsulated Diclofenac For Sonophoresis Induced Systemic Delivery," J. Microencapsulation, 1995, Vol. 12, No. 2, 149-154.	
CE3	Wess, L.: "All in the Family" BIOCENTURY, THE BERNSTEIN REPORT ON BIOBUSINESS, vol. 12, no. 22, 17 May 2004 (2004-05-17), pages A11-A12.	
CF3	Yuan, et al., "Cationic Liposome and Gene Transfer," Progress in Physiological Science, 28(2), pp. 163-165, 1997.	

*EXAMINER: Initial all reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 6311914	/Bruce Hissong/	Date Considered	12/10/2010
-------------------------------	-----------------	-----------------	------------

US100CS 6311914v1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /BH/



PTO/SB/02 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application No. (if known): 09/890,371

Attorney Docket No.: 2200437.00120US1

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

on August 6, 2007
Date



Signature

Kristen Moussalli

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 526-6000

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (241 References) (10 pages)